Poolbeg Pharma Company Description

Poolbeg Pharma PLC operates as a biopharmaceutical company and engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.

It is developing POLB 001, reinforcing its potential as a potent and selective Phase 2-ready p38 MAPK inhibitor with broad therapeutic applications.

POLB 001 is also in a Phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome.

It is also developing an oral encapsulated GLP-1R agonist for obesity and diabetes treatment. Additionally, its AI program is developing novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses.

Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, United Kingdom.

Poolbeg Pharma PLC

Country	United Kingdom
Founded	2021
Industry	Biotechnology
Sector	Healthcare
Employees	16
CEO	Jeremy Skillington

Contact Details

Address: 40 Bank Street London, E14 5NR United Kingdom
Phone	44 20 7183 1499
Website	poolbegpharma.com

Stock Details

Ticker Symbol	POLB
Exchange	London Stock Exchange AIM
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00BKPG7Z60
SIC Code	2834

Key Executives

Name	Position
Jeremy Skillington	Chief Executive Officer
Ian O'Connell	Chief Financial Officer
Laura Maher	Chief Operating Officer
Carol Dalton	Head of Investor Relations